ClinicalTrials.gg

Program

AZD1390

Also written as “[11C]AZD1390”.

Its studies are mostly in Glioblastoma · Neoplasms, led by AstraZeneca.

Furthest: phase 1, since Jun 29, 20173 company-led studies, 1 open or runningNext primary completion: Apr 12, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca31 open or runningphase 1since Jun 29, 2017Jun 29, 2017Apr 12, 2028phase 1 · NCT07643870
  • Named in AstraZeneca’s own pipeline as AZD1390, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2017First study: phase 1 study in Healthy Volunteer Male SubjectsFirst studyNCT03215381 · 8 enrolled · Sweden
  2. Nov 28, 2017Phase 1 study in GlioblastomaNCT03423628 · 159 enrolled · United States, Japan, United Kingdom
  3. Dec 18, 2025Phase 1 study in NeoplasmsNCT07643870 · 8 planned · United Kingdom

Ahead

  1. Apr 12, 2028Primary completion: phase 1 study in NeoplasmsNCT07643870

TargetBeta

“An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activat…”NCIt, read by Claude
“An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, ”NCIt, by rule

Other programs on ATM

ProgramCompanyFurthest phaseStudies
ATM Inhibitor SYH2051ruleCSPC Pharmaceutical Groupphase 23
TQB3117Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07643870Neoplasms · United Kingdom1Not yet recruitingApr 12, 20288
NCT03423628Glioblastoma · United States, Japan, United Kingdom1CompletedAug 31, 2026159
NCT03215381Healthy Volunteer Male Subjects · Sweden1CompletedFeb 19, 20188

How it is read

Names in the registry

  • “AZD1390”, 4 entries
  • “[11C]AZD1390”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.